

The Honorable Tina Liebling  
Chair, Minnesota House Health Finance and Policy Committee Minnesota  
State Capitol  
St. Paul, MN 55155

Cc: Senator Michelle Benson  
Chair, Minnesota Senate Health and Human Services Finance and Policy Committee

**Re: The House & Senate HFP/HHS Omnibus budget legislation – biosimilar provisions  
(oppose)**

Dear Representative Liebling,

I am writing you today to share my concern with you and your colleagues about legislation that has been proposed may increase the cost of my life saving medications here in Minnesota. I am a colon *cancer* patient and take several prescription medications every day to help keep my cancer in check and try to live a normal and healthy life. My medications help me do this. I'm also a volunteer for the Colorectal Cancer Coalition which is a national non profit organization headquartered right here in Minnesota. This organization, a member of the Global Colon Cancer Association, is one of the leading national organizations dedicated to raising awareness about the disease as well as serving patients like me.

If the legislation, HF1516, is included in your bill currently being considered I am afraid that my prescription medication could cost me more and possibly become unaffordable. While I know competition in the complex market of prescription drugs is a good thing, requiring very expensive medications to be covered no matter what seems like something that doesn't make any sense to me. I have read about the promise of biosimilar medications and hope that their development will eventually lead to reductions in the costs of medications like the ones that have been prescribed to treat my cancer.

However, understanding what the proposed legislation would do seems to me could only increase my healthcare costs. Please consider this when you think about including HF1516 language in the HFP/HHS Omnibus budget legislation.

Sincerely,

Jason Randall  
Stage IV Colon Cancer Survivor  
11624 Highway 55  
Minneapolis, MN 55441